BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 128,194 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its holdings in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 14.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 759,887 shares of the company's stock after selling 128,194 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 1.60% of Bicycle Therapeutics worth $17,196,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of BCYC. Avoro Capital Advisors LLC bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at about $14,168,000. Perceptive Advisors LLC bought a new stake in Bicycle Therapeutics in the second quarter valued at approximately $11,577,000. Principal Financial Group Inc. acquired a new stake in Bicycle Therapeutics during the 3rd quarter valued at approximately $10,028,000. Armistice Capital LLC raised its holdings in Bicycle Therapeutics by 17.9% during the 2nd quarter. Armistice Capital LLC now owns 1,972,000 shares of the company's stock worth $39,913,000 after purchasing an additional 300,000 shares during the last quarter. Finally, First Light Asset Management LLC lifted its position in shares of Bicycle Therapeutics by 16.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company's stock worth $28,028,000 after purchasing an additional 191,717 shares during the period. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BCYC shares. Needham & Company LLC reiterated a "buy" rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Stephens started coverage on Bicycle Therapeutics in a research report on Friday, November 8th. They issued an "equal weight" rating and a $25.00 price objective for the company. B. Riley lowered Bicycle Therapeutics from a "buy" rating to a "neutral" rating and cut their target price for the company from $33.00 to $28.00 in a research report on Wednesday, August 7th. Oppenheimer reiterated an "outperform" rating and issued a $48.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, August 7th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Bicycle Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $40.13.

Bicycle Therapeutics Trading Up 1.4 %

NASDAQ BCYC traded up $0.28 during trading hours on Friday, hitting $20.54. The company's stock had a trading volume of 536,420 shares, compared to its average volume of 450,627. The company has a market capitalization of $976.68 million, a PE ratio of -6.24 and a beta of 0.89. Bicycle Therapeutics plc has a 52 week low of $13.31 and a 52 week high of $28.67. The company's 50-day simple moving average is $23.97 and its two-hundred day simple moving average is $23.04.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to analysts' expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Bicycle Therapeutics's quarterly revenue was down 50.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.26) earnings per share. Research analysts anticipate that Bicycle Therapeutics plc will post -3.07 EPS for the current fiscal year.

Insider Activity

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 6,256 shares of the company's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the transaction, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. This represents a 24.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the sale, the chief executive officer now owns 380,864 shares in the company, valued at $8,478,032.64. The trade was a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,840 shares of company stock worth $259,128 over the last quarter. Insiders own 8.50% of the company's stock.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.